Agents

• Atezolizumab (MPDL3280A) (see Atezolizumab, Atezolizumab)
  • Pharmacology: monoclonal antibody against PD-L1, inhibiting the interaction of PD-L1 (B7-H1) with PD-1 and B7.1
• Pidilizumab (CT-011)
  • Pharmacology: monoclonal antibody against PD-1
• Nivolumab (Opdivo) (see Nivolumab, Nivolumab)
  • Pharmacology: fully human IgG4 monoclonal antibody against PD-1 (receptor), inhibiting interaction of the PD-L1 (B7-H1) and PD-L2 ligands (B7-DC) with PD-1
• Pembrolizumab (Keytruda) (see Pembrolizumab, Pembrolizumab)
  • Pharmacology: monoclonal antibody against PD-1 (receptor)

Pharmacology

• Programmed Cell Death Protein 1 (PD-1) is a Key Immune-Checkpoint Receptor Expressed by Activated T-Cells: it mediates immunosuppression

References

• xxx